RecruitingNCT06686979

PDO Based Drug Sensitive Test in R/M SGC

Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent/Metastatic Salivary Gland Cancer: A Prospective, Multicenter, Observational Study

Sponsor

Huashan Hospital

Enrollment

40 participants

Start Date

Mar 26, 2025

Study Type

OBSERVATIONAL

Conditions

Salivary Gland Cancers Patient Derived Organoid Drug Sensitive Test in Vitro

Summary

To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study uses small lab-grown tumor models (called organoids or PDOs) made from a patient's own salivary gland cancer tissue to test which drugs are likely to work best for that specific patient, helping to personalize treatment for recurrent or metastatic salivary gland cancer. **You may be eligible if...** - You have been confirmed to have recurrent or metastatic salivary gland carcinoma - Tumor tissue can be obtained for organoid culture - You are physically functional (ECOG 0–2) - Your life expectancy is more than 3 months - Your blood counts and organ function are within the required range **You may NOT be eligible if...** - Your cancer is not a true salivary gland cancer (e.g., squamous cell carcinoma, nasopharyngeal cancer) - You are allergic to the study drugs or any monoclonal antibodies - You are pregnant or breastfeeding - You have active HIV, uncontrolled hepatitis B or C, or serious heart disease - You have a serious psychiatric illness or substance abuse history Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention: Observational Cohort

The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.

Locations(2)

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06686979

Related Trials

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

NCT058843201 location

PDO Based Drug Sensitive Test in R/M HNSCC

NCT066863422 locations